CADL
- Candel Therapeutics, Inc.
()
Overview
Company Summary
Candel Therapeutics, Inc. is a biopharmaceutical company specializing in the development of innovative cancer treatments. Their primary focus is on creating therapies that harness the power of oncolytic viruses to target and eliminate cancer cells.
Oncolytic viruses are genetically engineered viruses that specifically infect and replicate within cancer cells, leading to their destruction. Candel Therapeutics aims to leverage this approach to develop safer and more effective treatments for various types of cancers.
The company utilizes a proprietary platform called Candel Core Technology to engineer these oncolytic viruses by modifying their genetic makeup. This technology allows for precise control over the virus's ability to infect cancer cells, ensuring safety and effectiveness while minimizing harm to healthy cells.
Candel Therapeutics' pipeline includes a range of potential therapies for different types of cancers. They conduct rigorous preclinical and clinical studies to evaluate the safety and efficacy of their treatments, working towards regulatory approval and commercialization.
In addition to their oncology focus, Candel also explores the potential of their viral-based platform in other therapeutic areas, such as infectious diseases and genetic disorders. This versatility allows them to explore opportunities beyond cancer treatment and potentially contribute to advancements in multiple medical fields.
Overall, Candel Therapeutics is dedicated to researching, developing, and commercializing innovative oncolytic virus therapies with the ultimate goal of improving outcomes for patients with cancer.